Skip to content
value.today

Hypera S.A.: peers

Change the peers

Hypera S.A. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Regencell Bioscience Holdings Limited, Dermapharm Holding SE, Supernus Pharmaceuticals, Inc., Trulieve Cannabis Corp., Almirall, S.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Hypera S.A., Regencell Bioscience Holdings Limited, Dermapharm Holding SE, Supernus Pharmaceuticals, Inc., Perrigo Company plc, Trulieve Cannabis Corp., Bausch Health Companies Inc., Almirall, S.A. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureHypera S.A.base
HYPE3.SA · 🇧🇷 BR
Percentile in Healthcare
Percentile in Brazil
Regencell Bioscience Holdings Limited
RGC · 🇭🇰 HK
Percentile in Healthcare
Percentile in Hong Kong
Dermapharm Holding SE
DMP.F · 🇩🇪 DE
Percentile in Healthcare
Percentile in Germany
Supernus Pharmaceuticals, Inc.
SUPN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Perrigo Company plc
PRGO · 🇮🇪 IE
Percentile in Healthcare
Percentile in Ireland
Trulieve Cannabis Corp.
TCNNF · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Bausch Health Companies Inc.
BHC.TO · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
Almirall, S.A.
ALM.MC · 🇪🇸 ES
Percentile in Healthcare
Percentile in Spain
Group median
Size
Market cap (Better neither way: ranked highest first)$2.5 BNov 18, 2026 · Market dataEstimate4th of 8$2.7 BAug 1, 2026 · Market data3rd of 8$2.3 BAug 1, 2026 · Market data5th of 8$2.8 BAug 1, 2026 · Market data2nd of 8$2.2 BOct 30, 2026 · Market data6th of 8$2.1 BAug 1, 2026 · Market data7th of 8$3.1 BOct 31, 2026 · Market data1st of 8$2.0 Blast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8$2.4 B8 ranked
Revenue (Better neither way: ranked highest first)——————$719 MFY2025 · SEC5th of 5$4.3 BFY2025 · SEC2nd of 5$1.2 BFY2025 · SEC4th of 5$10.3 BFY2025 · SEC1st of 5$1.2 BFY2025 · ESEF3rd of 5$1.2 B5 ranked
Net income (Higher is better)——$-12 MFY2026 · SEC4th of 7$148 MFY2025 · Wikidata2nd of 7$-39 MFY2025 · SEC5th of 7$-1.4 BFY2025 · SEC7th of 7$-116 MFY2025 · SEC6th of 7$157 MFY2025 · SEC1st of 7$52 MFY2025 · ESEF3rd of 7$-12 M7 ranked
Employees (Better neither way: ranked highest first)9,000As on 2022 · Profile2nd of 7——3,4972023 · Profile5th of 7575As on 2021 · Profile7th of 78,900As on 2022 · Profile3rd of 74,700As on 2020 · Profile4th of 721,600As on 2020 · Profile1st of 71,7732019 · Profile6th of 74,7007 ranked
Growth
Market cap change, 30 days (Higher is better)————————————+40.6%30 days to Oct 31, 2026 · Market dataonly one with it——+40.6%—
Revenue growth (Higher is better)————————————+8.6%FY2025 · SEC2nd of 547th57th-2.8%FY2025 · SEC5th of 521st16th-0.5%FY2025 · SEC4th of 525th28th+6.7%FY2025 · SEC3rd of 542nd44th+17.1%FY2025 · ESEF1st of 563rd76th+6.7%5 ranked
Revenue growth, 3 years a year (Higher is better)————————————+2.5%FY2025 · SEC2nd of 435th42nd-1.5%FY2025 · SEC4th of 423rd12th-1.0%FY2025 · SEC3rd of 424th29th+8.1%FY2025 · SEC1st of 449th54th————+0.8%4 ranked
Earnings per share growth (Higher is better)————————————————————————————+358.4%FY2025 · ESEFonly one with it96th99th+358.4%—
Margins and returns
Gross margin (Higher is better)————————————89.6%FY2025 · SEC1st of 392nd97th35.1%FY2025 · SEC3rd of 321st55th60.2%FY2025 · SEC2nd of 353rd74th————————60.2%3 ranked
Operating margin (Higher is better)————————————-8.7%FY2025 · SEC4th of 549th28th-26.4%FY2025 · SEC5th of 539th6th12.2%FY2025 · SEC2nd of 576th73rd17.7%FY2025 · SEC1st of 585th64th6.6%FY2025 · ESEF3rd of 567th36th6.6%5 ranked
Net margin (Higher is better)————————————-5.4%FY2025 · SEC3rd of 553rd33rd-33.5%FY2025 · SEC5th of 536th12th-9.8%FY2025 · SEC4th of 548th27th1.5%FY2025 · SEC2nd of 563rd44th4.2%FY2025 · ESEF1st of 568th45th-5.4%5 ranked
Free cash flow margin (Higher is better)————————————6.4%FY2025 · SEC4th of 565th59th3.4%FY2025 · SEC5th of 559th21st19.4%FY2025 · SEC1st of 587th87th9.8%FY2025 · SEC3rd of 571st64th12.6%FY2025 · ESEF2nd of 576th74th9.8%5 ranked
Return on equity (Higher is better)————-128.5%FY2026 · SEC5th of 518th12th————-3.7%FY2025 · SEC2nd of 570th38th-39.3%FY2025 · SEC4th of 549th9th-9.7%FY2025 · SEC3rd of 566th33rd————3.2%FY2025 · ESEF1st of 575th24th-9.7%5 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)7.0×price Nov 18, 2026 · Market dataonly one with it8th41st————15.7×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————————————————7.0×—
Price to sales (Better neither way: ranked highest first)1.6×price Nov 18, 2026 · Market data1st of 327th72nd————2.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price3.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price0.5×price Oct 30, 2026 · Market data2nd of 39th29th2.0×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price0.3×price Oct 31, 2026 · Market data3rd of 34th6th————0.5×3 ranked
Price to book (Better neither way: ranked highest first)1.1×price Nov 18, 2026 · Market data1st of 221st41st201.9×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price4.0×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price2.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price0.8×price Oct 30, 2026 · Market data2nd of 214th4th1.9×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————0.9×2 ranked
Free cash flow yield (Higher is better)————-0.1%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————1.6%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price6.6%price Oct 30, 2026 · Market data2nd of 291st46th10.7%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price32.6%price Oct 31, 2026 · Market data1st of 299th99th————19.6%2 ranked
Financial strength
Debt to equity (Lower is better)————————————————1.2×FY2025 · SEC2nd of 279th78th0.1×FY2025 · SEC1st of 223rd16th————————0.7×2 ranked
Net debt to EBITDA (Lower is better)————————————————————-0.5×FY2025 · SEC1st of 220th12th6.5×FY2025 · SEC2nd of 291st74th————3.0×2 ranked
Interest cover (Higher is better)————————————————————————1.1×FY2025 · SEConly one with it76th56th————1.1×—
Piotroski F-score (Higher is better)————————4 of 9FY2025 · SEC2nd of 26 of 9FY2025 · SEC1st of 2————5.0 of 92 ranked
Scorecard
Scorecard (Higher is better)——2 of 8FY2026 · Scorecard7th of 72 of 2FY2025 · Scorecard1st of 76 of 15FY2025 · Scorecard5th of 79 of 26FY2025 · Scorecard6th of 77 of 17FY2025 · Scorecard4th of 714 of 22FY2025 · Scorecard3rd of 74 of 5FY2025 · Scorecard2nd of 741% passed7 ranked
Valuation checks (Higher is better)————————3 of 6FY2025 · Scorecard1st of 2——2 of 6FY2025 · Scorecard2nd of 2——42% passed2 ranked
Growth checks (Higher is better)——0 of 2FY2026 · Scorecard5th of 71 of 1FY2025 · Scorecard1st of 72 of 6FY2025 · Scorecard4th of 70 of 6FY2025 · Scorecard5th of 70 of 6FY2025 · Scorecard5th of 76 of 6FY2025 · Scorecard1st of 72 of 2FY2025 · Scorecard1st of 733% passed7 ranked
Profitability checks (Higher is better)——0 of 3FY2026 · Scorecard5th of 71 of 1FY2025 · Scorecard1st of 70 of 5FY2025 · Scorecard5th of 70 of 5FY2025 · Scorecard5th of 72 of 5FY2025 · Scorecard4th of 73 of 4FY2025 · Scorecard2nd of 72 of 3FY2025 · Scorecard3rd of 740% passed7 ranked
Financial health checks (Higher is better)——1 of 2FY2026 · Scorecard3rd of 5——3 of 3FY2025 · Scorecard1st of 52 of 4FY2025 · Scorecard3rd of 54 of 5FY2025 · Scorecard2nd of 52 of 5FY2025 · Scorecard5th of 5——50% passed5 ranked
Shareholder returns checks (Higher is better)——1 of 1FY2026 · Scorecard1st of 5——1 of 1FY2025 · Scorecard1st of 54 of 5FY2025 · Scorecard5th of 51 of 1FY2025 · Scorecard1st of 51 of 1FY2025 · Scorecard1st of 5——100% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——0.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4——97.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4110.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4——63.4%2026-Q2 · 13F3rd of 4——80.7%4 ranked
Institutions holding (Better neither way: ranked highest first)——312026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4——2942026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 43362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4——2202026-Q2 · 13F3rd of 4——2574 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——+0.1 pp2026-Q2 against 2026-Q1 · 13F4th of 4——+3.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 4+6.6 pp2026-Q2 against 2026-Q1 · 13F1st of 4——+1.1 pp2026-Q2 against 2026-Q1 · 13F3rd of 4——+2.3 pp4 ranked
Dividends
Dividend yield (Higher is better)————————————————7.2%FY2025 · SEConly one with it95th—————————————7.2%—
Shareholder yield (Higher is better)————————————————7.2%FY2025 · SEConly one with it86th86th————————————7.2%—
Dividend per share (Better neither way: ranked highest first)————————$1.16FY2025 · SEConly one with it——————$1.16—
Years of dividend raises (Higher is better)————————9to 2025 · SEConly one with it——————9—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Hypera S.A.: Estimate: B3 São Paulo close of 18 Nov 2026 x the share count implied by the market cap reported for 01 Aug 2026; Regencell Bioscience Holdings Limited: How market caps are worked out; Dermapharm Holding SE: How market caps are worked out; Supernus Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Perrigo Company plc: How market caps are worked out; Trulieve Cannabis Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Bausch Health Companies Inc.: TMX Group, TSX and TSXV listed issuers (monthly); Almirall, S.A.: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Hypera S.A.———
Regencell Bioscience Holdings Limited———
Dermapharm Holding SE———
Supernus Pharmaceuticals, Inc.-8.7%FY2025
49th percentile in Healthcaremedian -7.7%, 674 companies
28th percentile in USAmedian 3.5%, 2,594 companies
Perrigo Company plc-26.4%FY2025
39th percentile in Healthcaremedian -7.7%, 674 companies
6th percentile in Irelandmedian 9.3%, 25 companies
Trulieve Cannabis Corp.12.2%FY2025
76th percentile in Healthcaremedian -7.7%, 674 companies
73rd percentile in USAmedian 3.5%, 2,594 companies
Bausch Health Companies Inc.17.7%FY2025
85th percentile in Healthcaremedian -7.7%, 674 companies
64th percentile in Canadamedian 8.7%, 114 companies
Almirall, S.A.6.6%FY2025
67th percentile in Healthcaremedian -7.7%, 674 companies
36th percentile in Spainmedian 9.2%, 79 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$2.6 B$5.2 B$7.8 B$10.4 B20102012201420162018202020222024Dermapharm Holding SE $1.2 BSupernus Pharmaceuticals, Inc. $719 MPerrigo Company plc $4.3 BTrulieve Cannabis Corp. $1.2 BBausch Health Companies Inc. $10.3 BAlmirall, S.A. $1.2 B

Rank in the group

1st2nd3rd4th5th6th201120122013201420152016201720182019202020212022202320242025Dermapharm Holding SE: 3rd of 4 in 2014Dermapharm Holding SE: 3rd of 4 in 2015Dermapharm Holding SE: 3rd of 4 in 2016Dermapharm Holding SE: 3rd of 4 in 2017Dermapharm Holding SE: 3rd of 4 in 2018Dermapharm Holding SE: 4th of 6 in 2019Dermapharm Holding SE: 3rd of 5 in 2020Dermapharm Holding SE: 3rd of 5 in 2021Dermapharm Holding SE: 4th of 5 in 2022Dermapharm Holding SE: 3rd of 5 in 2023Dermapharm Holding SESupernus Pharmaceuticals, Inc.: 2nd of 2 in 2011Supernus Pharmaceuticals, Inc.: 3rd of 3 in 2012Supernus Pharmaceuticals, Inc.: 3rd of 3 in 2013Supernus Pharmaceuticals, Inc.: 4th of 4 in 2014Supernus Pharmaceuticals, Inc.: 4th of 4 in 2015Supernus Pharmaceuticals, Inc.: 4th of 4 in 2016Supernus Pharmaceuticals, Inc.: 4th of 4 in 2017Supernus Pharmaceuticals, Inc.: 4th of 4 in 2018Supernus Pharmaceuticals, Inc.: 5th of 6 in 2019Supernus Pharmaceuticals, Inc.: 5th of 5 in 2020Supernus Pharmaceuticals, Inc.: 5th of 5 in 2021Supernus Pharmaceuticals, Inc.: 5th of 5 in 2022Supernus Pharmaceuticals, Inc.: 5th of 5 in 2023Supernus Pharmaceuticals, Inc.: 5th of 5 in 2024Supernus Pharmaceuticals, Inc.: 5th of 5 in 2025Supernus Pharmaceuticals, Perrigo Company plc: 2nd of 3 in 2012Perrigo Company plc: 2nd of 3 in 2013Perrigo Company plc: 2nd of 4 in 2014Perrigo Company plc: 2nd of 4 in 2015Perrigo Company plc: 2nd of 4 in 2016Perrigo Company plc: 2nd of 4 in 2017Perrigo Company plc: 2nd of 4 in 2018Perrigo Company plc: 2nd of 6 in 2019Perrigo Company plc: 2nd of 5 in 2020Perrigo Company plc: 2nd of 5 in 2021Perrigo Company plc: 2nd of 5 in 2022Perrigo Company plc: 2nd of 5 in 2023Perrigo Company plc: 2nd of 5 in 2024Perrigo Company plc: 2nd of 5 in 2025Perrigo Company plcTrulieve Cannabis Corp.: 6th of 6 in 2019Trulieve Cannabis Corp.: 4th of 5 in 2020Trulieve Cannabis Corp.: 4th of 5 in 2021Trulieve Cannabis Corp.: 3rd of 5 in 2022Trulieve Cannabis Corp.: 4th of 5 in 2023Trulieve Cannabis Corp.: 3rd of 5 in 2024Trulieve Cannabis Corp.: 4th of 5 in 2025Trulieve Cannabis Corp.Bausch Health Companies Inc.: 1st of 2 in 2011Bausch Health Companies Inc.: 1st of 3 in 2012Bausch Health Companies Inc.: 1st of 3 in 2013Bausch Health Companies Inc.: 1st of 4 in 2014Bausch Health Companies Inc.: 1st of 4 in 2015Bausch Health Companies Inc.: 1st of 4 in 2016Bausch Health Companies Inc.: 1st of 4 in 2017Bausch Health Companies Inc.: 1st of 4 in 2018Bausch Health Companies Inc.: 1st of 6 in 2019Bausch Health Companies Inc.: 1st of 5 in 2020Bausch Health Companies Inc.: 1st of 5 in 2021Bausch Health Companies Inc.: 1st of 5 in 2022Bausch Health Companies Inc.: 1st of 5 in 2023Bausch Health Companies Inc.: 1st of 5 in 2024Bausch Health Companies Inc.: 1st of 5 in 2025Bausch Health Companies InAlmirall, S.A.: 3rd of 6 in 2019Almirall, S.A.: 4th of 5 in 2024Almirall, S.A.: 3rd of 5 in 2025Almirall, S.A.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearHypera S.A.Regencell Bioscience Holdings LimitedDermapharm Holding SESupernus Pharmaceuticals, Inc.Perrigo Company plcTrulieve Cannabis Corp.Bausch Health Companies Inc.Almirall, S.A.
2025———$719 MSEC5th$4.3 BSEC2nd$1.2 BSEC4th$10.3 BSEC1st$1.2 BESEF3rd
2024———$662 MSEC5th$4.4 BSEC2nd$1.2 BSEC3rd$9.6 BSEC1st$1.1 BESEF4th
2023——$1.2 BWD3rd$608 MSEC5th$4.7 BSEC2nd$1.1 BSEC4th$8.8 BSEC1st—
2022——$1.1 BWD4th$667 MSEC5th$4.5 BSEC2nd$1.2 BSEC3rd$8.1 BSEC1st—
2021——$1.1 BWD3rd$580 MSEC5th$4.1 BSEC2nd$932 MSEC4th$8.4 BSEC1st—
2020——$905 MWD3rd$520 MSEC5th$4.1 BSEC2nd$522 MSEC4th$8.0 BSEC1st—
2019——$785 MWD4th$393 MSEC5th$3.9 BSEC2nd$253 MSEC6th$8.6 BSEC1st$957 MWD3rd
2018——$675 MWD3rd$409 MSEC4th$4.7 BSEC2nd—$8.4 BSEC1st—
2017——$527 MWD3rd$302 MSEC4th$4.9 BSEC2nd—$8.7 BSEC1st—
2016——$492 MWD3rd$215 MSEC4th$5.3 BSEC2nd—$9.7 BSEC1st—
2015——$427 MWD3rd$147 MSEC4th$4.2 BSEC2nd—$10.4 BSEC1st—
2014——$519 MWD3rd$93 MSEC4th$3.9 BSEC2nd—$8.2 BSEC1st—

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Hypera S.A.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Regencell Bioscience Holdings LimitedRGC · 🇭🇰 Hong Kong
    Same industry: Pharmaceutical · Similar size: $2.7 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $2.7 B (Aug 1, 2026)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Dermapharm Holding SEDMP.F · 🇩🇪 Germany
    Same industry: Pharmaceutical · Similar size: $2.3 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $2.3 B (Aug 1, 2026) · revenue $1.1 B (year to December 2022)
    84 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Supernus Pharmaceuticals, Inc.SUPN · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $2.8 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $2.8 B (Aug 1, 2026) · revenue $719 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Perrigo Company plcPRGO · 🇮🇪 Ireland
    Same industry: Pharmaceutical · Similar size: $2.2 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $2.2 B (Oct 30, 2026) · revenue $4.3 B (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Trulieve Cannabis Corp.TCNNF · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $2.1 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $2.1 B (Aug 1, 2026) · revenue $1.2 B (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Bausch Health Companies Inc.BHC.TO · 🇨🇦 Canada
    Same industry: Pharmaceutical · Similar size: $3.1 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $3.1 B (Oct 31, 2026) · revenue $10.3 B (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Almirall, S.A.ALM.MC · 🇪🇸 Spain
    Same industry: Pharmaceutical · Similar size: $2.0 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $2.0 B (last known, Jan 5, 2024) · revenue $1.2 B (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    In the group
  • Fagron NVFAGR.BR · 🇧🇪 Belgium
    Same industry: Pharmaceutical · Similar size: $1.9 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $1.9 B (Aug 1, 2026) · revenue $944 M (year to December 2024)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Dimed Distribuidora de MedicamentosPNVL3.SA · 🇧🇷 Brazil
    Same industry: Pharmaceutical · 6.5× smaller by market cap · Same country: Brazil
    Market cap $388 M (last known, Jan 5, 2024)
    83 of 100 (industry or sector 50 + size 18 + country 15)
    + Add
  • Organon & Co.OGN · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $3.6 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $3.6 B (Oct 19, 2026) · revenue $6.2 B (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Faes Farma, S.A.FAE.MC · 🇪🇸 Spain
    Same industry: Pharmaceutical · Similar size: $1.7 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $1.7 B (Aug 1, 2026) · revenue $688 M (year to December 2025)
    82 of 100 (industry or sector 50 + size 27 + figures on file 5)
    + Add
  • ANI Pharmaceuticals, Inc.ANIP · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $1.6 B market cap against $2.5 B · Ratios of the last two fiscal years on file
    Market cap $1.6 B (Oct 9, 2026) · revenue $883 M (year to December 2025)
    82 of 100 (industry or sector 50 + size 27 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.